Shanghai Henlius Biotech Inc
HKEX:2696
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.7
23.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Shanghai Henlius Biotech Inc
Total Receivables
Shanghai Henlius Biotech Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Henlius Biotech Inc
HKEX:2696
|
Total Receivables
¥865.2m
|
CAGR 3-Years
29%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Total Receivables
¥3.2B
|
CAGR 3-Years
77%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Total Receivables
¥3.1B
|
CAGR 3-Years
62%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Total Receivables
¥1.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
0%
|
CAGR 10-Years
24%
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Total Receivables
¥25.5B
|
CAGR 3-Years
43%
|
CAGR 5-Years
44%
|
CAGR 10-Years
48%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Total Receivables
¥230.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
|
Shanghai Henlius Biotech Inc
Glance View
Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.
See Also
What is Shanghai Henlius Biotech Inc's Total Receivables?
Total Receivables
865.2m
CNY
Based on the financial report for Dec 31, 2023, Shanghai Henlius Biotech Inc's Total Receivables amounts to 865.2m CNY.
What is Shanghai Henlius Biotech Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
71%
Over the last year, the Total Receivables growth was 70%. The average annual Total Receivables growth rates for Shanghai Henlius Biotech Inc have been 29% over the past three years , 71% over the past five years .
You don't have any saved screeners yet
